<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Plant Sci</journal-id><journal-id journal-id-type="iso-abbrev">Front Plant Sci</journal-id><journal-id journal-id-type="publisher-id">Front. Plant Sci.</journal-id><journal-title-group><journal-title>Frontiers in Plant Science</journal-title></journal-title-group><issn pub-type="epub">1664-462X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7733993</article-id><article-id pub-id-type="doi">10.3389/fpls.2020.601316</article-id><article-categories><subj-group subj-group-type="heading"><subject>Plant Science</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Docking Characterization and <italic>in vitro</italic> Inhibitory Activity of Flavan-3-ols and Dimeric Proanthocyanidins Against the Main Protease Activity of SARS-Cov-2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Yue</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/403363/overview"/></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>De-Yu</given-names></name><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/45963/overview"/></contrib></contrib-group><aff><institution>Department of Plant and Microbial Biology, North Carolina State University</institution>, <addr-line>Raleigh, NC</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Guodong Wang, Chinese Academy of Sciences, China</p></fn><fn fn-type="edited-by"><p>Reviewed by: Hiroshi Noguchi, Nihon Pharmaceutical University, Japan; Ericsson Coy-Barrera, Universidad Militar Nueva Granada, Colombia</p></fn><corresp id="c001">*Correspondence: De-Yu Xie <email>dxie@ncsu.edu</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Plant Metabolism and Chemodiversity, a section of the journal Frontiers in Plant Science</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>11</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>11</volume><elocation-id>601316</elocation-id><history><date date-type="received"><day>31</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>06</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Zhu and Xie.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Zhu and Xie</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>We report to use the main protease (M<sup>pro</sup>) of SARS-Cov-2 to screen plant flavan-3-ols and proanthocyanidins. Twelve compounds, (&#x02013;)-afzelechin (AF), (&#x02013;)-epiafzelechin (EAF), (+)-catechin (CA), (&#x02013;)-epicatechin (EC), (+)-gallocatechin (GC), (&#x02013;)-epigallocatechin (EGC), (+)-catechin-3-O-gallate (CAG), (&#x02013;)-epicatechin-3-O-gallate (ECG), (&#x02013;)-gallocatechin-3-O-gallate (GCG), (&#x02013;)-epigallocatechin-3-O-gallate (EGCG), procyanidin A2 (PA2), and procyanidin B2 (PB2), were selected for docking simulation. The resulting data predicted that all 12 metabolites could bind to M<sup>pro</sup>. The affinity scores of PA2 and PB2 were predicted to be &#x02212;9.2, followed by ECG, GCG, EGCG, and CAG, &#x02212;8.3 to &#x02212;8.7, and then six flavan-3-ol aglycones, &#x02212;7.0 to &#x02212;7.7. Docking characterization predicted that these compounds bound to three or four subsites (S1, S1&#x02032;, S2, and S4) in the binding pocket of M<sup>pro</sup> via different spatial ways and various formation of one to four hydrogen bonds. <italic>In vitro</italic> analysis with 10 available compounds showed that CAG, ECG, GCG, EGCG, and PB2 inhibited the M<sup>pro</sup> activity with an IC<sub>50</sub> value, 2.98 &#x000b1; 0.21, 5.21 &#x000b1; 0.5, 6.38 &#x000b1; 0.5, 7.51 &#x000b1; 0.21, and 75.3 &#x000b1; 1.29 &#x003bc;M, respectively, while CA, EC, EGC, GC, and PA2 did not have inhibitory activities. To further substantiate the inhibitory activities, extracts prepared from green tea (GT), two muscadine grapes (MG), cacao, and dark chocolate (DC), which are rich in CAG, ECG, GAG, EGCG, or/and PB2, were used for inhibitory assay. The resulting data showed that GT, two MG, cacao, and DC extracts inhibited the M<sup>pro</sup> activity with an IC<sub>50</sub> value, 2.84 &#x000b1; 0.25, 29.54 &#x000b1; 0.41, 29.93 &#x000b1; 0.83, 153.3 &#x000b1; 47.3, and 256.39 &#x000b1; 66.3 &#x003bc;g/ml, respectively. These findings indicate that on the one hand, the structural features of flavan-3-ols are closely associated with the affinity scores; on the other hand, the galloylation and oligomeric types of flavan-3-ols are critical in creating the inhibitory activity against the M<sup>pro</sup> activity.</p></abstract><kwd-group><kwd>flavan-3-ols</kwd><kwd>flavan-3-ol gallates</kwd><kwd>procyanidins</kwd><kwd>COVID-19</kwd><kwd>green tea</kwd><kwd>muscadine grape</kwd><kwd>cacao</kwd><kwd>dark chocolate</kwd></kwd-group><counts><fig-count count="7"/><table-count count="1"/><equation-count count="0"/><ref-count count="61"/><page-count count="14"/><word-count count="8311"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>SARS-CoV-2 is a novel severe acute respiratory syndrome-related coronavirus strain and highly contagious to humans (<xref ref-type="fig" rid="F1">Figure 1</xref>). Its infection on humans was reported in the early December of 2019 in Wuhan, China (Wang C. et al., <xref rid="B48" ref-type="bibr">2020</xref>; Wu et al., <xref rid="B54" ref-type="bibr">2020</xref>). On January 30, 2020, The World Health Organization (WHO) declared the outbreak of the coronavirus disease 2019 (COVID-19) emergency (World Health Organization, <xref rid="B52" ref-type="bibr">2020a</xref>). On March 11, 2020, WHO announced the COVID-19 pandemic (World Health Organization, <xref rid="B53" ref-type="bibr">2020b</xref>). As of October 22, 2020, it has infected ~41,561,983 people and caused ~1,135,289 deaths worldwide (data source from Johns Hopkins Coronavirus Resource Center). These numbers are continuously increasing every day. Extremely sadly, the humans do not know when this pandemic will end. Although hydroxychloroquine, chloroquine, and remdesivir were recommended for treating COVID-19 (Colson et al., <xref rid="B5" ref-type="bibr">2020</xref>; Sehailia and Chemat, <xref rid="B42" ref-type="bibr">2020</xref>; Wang M. et al., <xref rid="B49" ref-type="bibr">2020</xref>), their therapeutic effects still remain for studies. For example, a new study showed that chloroquine could not treat COVID-19 (Hoffmann et al., <xref rid="B16" ref-type="bibr">2020</xref>). Although 300 trials with different anti-virus medicines are being performed (Sanders et al., <xref rid="B39" ref-type="bibr">2020</xref>), such as lopinavir and ritonavir (Cao et al., <xref rid="B2" ref-type="bibr">2020</xref>), the fact is that no medicines show therapeutic effectiveness. Although in June 2020, dexamethasone, a steroid, was publically reported to decrease the death risk of COVID-19 patients (Khan and Htar, <xref rid="B22" ref-type="bibr">2020</xref>; Selvaraj et al., <xref rid="B43" ref-type="bibr">2020</xref>), more trials need to be performed to demonstrate its effectiveness. Furthermore, different proteins or genes of SARS-Cov-2, such as the main protease (<xref ref-type="fig" rid="F1">Figure 1</xref>), have been targeted to screen medicines, however, no small molecules have been conclusively shown to be able to treat COVID-19 patients (Dai W. et al., <xref rid="B6" ref-type="bibr">2020</xref>; Zhang et al., <xref rid="B59" ref-type="bibr">2020</xref>). Currently, the humans are placing a hope on vaccines. However, no effective vaccines are ready for prevention. The potential risks of vaccines remain largely unknown. Making matters worse, more studies have shown that the originality and the transmission of this contagious virus are more complicated than the humans know. Studies have shown that in addition to aerosol transmission, this virus can be transmitted through gastrointestinal infection (Lamers et al., <xref rid="B23" ref-type="bibr">2020</xref>; Xiao et al., <xref rid="B55" ref-type="bibr">2020</xref>) and can stably stay for 3 h in air and 72 h on plastic and steal surfaces (van Doremalen et al., <xref rid="B47" ref-type="bibr">2020</xref>). In addition to causing lung diseases, this virus has been found to cause other health complications, such as abdominal pain (Lamers et al., <xref rid="B23" ref-type="bibr">2020</xref>) and neurologic abnormality (Helms et al., <xref rid="B15" ref-type="bibr">2020</xref>). To the whole world surprise, one newest study revealed that SARS-Cov-2 existed in wastewater that had been stored in Barcelona, Spain since March 2019 (Chavarria-Mir&#x000f3; et al., <xref rid="B3" ref-type="bibr">2020</xref>), the time of which was 9 months earlier than the first report from Wuhan. This finding implies that SARS-Cov-2 might have been transmitted in humans before the outbreak. In summary, no medicines can treat COVID-19 and no vaccines can prevent this contagious disease. Therefore, effective treatments and preventions are urgently needed.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>A simplified diagram showing the essential function of the main protease involved in SARS-Cov-2 replication in infected host cells.</p></caption><graphic xlink:href="fpls-11-601316-g0001"/></fig><p>Flavan-3-ols and proanthocyanidins (PAs) are two groups of plant flavonoids (<xref ref-type="fig" rid="F2">Figure 2</xref>; Xie and Dixon, <xref rid="B56" ref-type="bibr">2005</xref>). They commonly exist in fruits, food products, and beverages, such as grape (Iacopini et al., <xref rid="B18" ref-type="bibr">2008</xref>; Zhu et al., <xref rid="B61" ref-type="bibr">2014</xref>; Yuzuak et al., <xref rid="B58" ref-type="bibr">2018</xref>; Rousserie et al., <xref rid="B38" ref-type="bibr">2019</xref>), strawberry (Lopez-Serrano and Barcelo, <xref rid="B28" ref-type="bibr">1997</xref>; Fossen et al., <xref rid="B12" ref-type="bibr">2004</xref>; Fischer et al., <xref rid="B9" ref-type="bibr">2014</xref>), persimmon (Akagi et al., <xref rid="B1" ref-type="bibr">2009</xref>), cranberry (Foo et al., <xref rid="B10" ref-type="bibr">2000a</xref>,<xref rid="B11" ref-type="bibr">b</xref>), blueberry (Gu et al., <xref rid="B14" ref-type="bibr">2002</xref>), cacao nuts (Murphy et al., <xref rid="B33" ref-type="bibr">2003</xref>; Miller et al., <xref rid="B30" ref-type="bibr">2009</xref>), chocolate (Schewe et al., <xref rid="B40" ref-type="bibr">2002</xref>; Serafini et al., <xref rid="B44" ref-type="bibr">2003</xref>), green tea (Liu et al., <xref rid="B26" ref-type="bibr">2012</xref>; Zhao et al., <xref rid="B60" ref-type="bibr">2017</xref>; Wang P. et al., <xref rid="B50" ref-type="bibr">2020</xref>), and wines (Monagas et al., <xref rid="B32" ref-type="bibr">2003</xref>). Common flavan-3-ol aglycones in these plant products include (&#x02013;)-epicatechin (EC), (+)-catechin (CA), (&#x02013;)-epigallocatechin (EGC), (+)-gallocatechin (GC), (&#x02013;)-epiafzelechin (EAF), and (+)-afzelechin (AF) (<xref ref-type="fig" rid="F2">Figure 2</xref>; Xie and Dixon, <xref rid="B56" ref-type="bibr">2005</xref>). Common flavan-3-ol gallates include (&#x02013;)-epicatechin-3-O-gallate (ECG), (+)-catechin-3-O-gallate (CAG), (&#x02013;)-gallatechin-3-O-gallate (GCG), (&#x02013;)-epigallocatechin-3-O-galloate (EGCG), which are highly abundant in green tea (Dai X. et al., <xref rid="B7" ref-type="bibr">2020</xref>; Wang P. et al., <xref rid="B50" ref-type="bibr">2020</xref>). PAs are oligomeric or polymeric flavan-3-ols. In PAs, the lowest and upper units are termed as the starter and extension units, which are linked by interflavan bonds formed between the C<sub>8</sub> or C<sub>6</sub> of a lower unit and the C<sub>4</sub> of an upper unit (<xref ref-type="fig" rid="F2">Figure 2</xref>). In addition, a second linkage is a C<sub>2</sub>-O-C<sub>7</sub> ether bond between the starter unit and the extension unit. Based on the linkage numbers, PAs are classified into two types of structures, the dominant B-type characterized with an interflavan bond only and the uncommon A-type featured with an interflavan bond and an ether linkage (Xie and Dixon, <xref rid="B56" ref-type="bibr">2005</xref>). Common dimeric B-types in fruits and beverages include procyanidin B1, B2, B3, and B4. Two examples of dimeric A-type PAs are procyanidin A1 and A2 (Xie and Dixon, <xref rid="B56" ref-type="bibr">2005</xref>). Flavan-3-ols and PAs are potent antioxidants with multiple benefits to human health (Xie and Dixon, <xref rid="B56" ref-type="bibr">2005</xref>). Multiple compounds from these two groups, such as CA, EPC, EGC, EGCG, procyanidin B2, and procyanidin A2 (<xref ref-type="fig" rid="F2">Figure 2</xref>), have been shown to have antiviral function (de Bruyne et al., <xref rid="B8" ref-type="bibr">1999</xref>; Iwasawa et al., <xref rid="B19" ref-type="bibr">2009</xref>), antibacterial activity (Molan et al., <xref rid="B31" ref-type="bibr">2001</xref>; Howell et al., <xref rid="B17" ref-type="bibr">2005</xref>), anticancer (Ohata et al., <xref rid="B34" ref-type="bibr">2005</xref>; Suganuma et al., <xref rid="B45" ref-type="bibr">2011</xref>), anti-cardiovascular diseases (Loke et al., <xref rid="B27" ref-type="bibr">2008</xref>; Panneerselvam et al., <xref rid="B35" ref-type="bibr">2010</xref>; MacRae et al., <xref rid="B29" ref-type="bibr">2019</xref>), and anti-aging diseases (Levites et al., <xref rid="B24" ref-type="bibr">2003</xref>; Li et al., <xref rid="B25" ref-type="bibr">2004</xref>; Weinreb et al., <xref rid="B51" ref-type="bibr">2004</xref>). In particular, the anti-viral activity suggests that flavan-3-ols and PAs are appropriate targets for screening potential anti-SARS-Cov-2 medicines.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Structures of (+)-afzelechin, (&#x02013;)-epiafzelechin, (+)-catechin, (&#x02013;)-epicatechin, (+)-gallocatechin, (&#x02013;)-epigallocatechin, (&#x02013;)-catechin-3-O-gallate, (&#x02013;)-epicatechin-3-O-gallate, (&#x02013;)-gallocatechin-3-O-gallate, and (&#x02013;)-epigallocatechin-3-O-gallate, procyanidin B1 and B2, and procyanidin A1 and A2.</p></caption><graphic xlink:href="fpls-11-601316-g0002"/></fig><p>In this study, our goal was to use the M<sup>pro</sup> of SARS-Cov-2 for docking simulation to screen flavan-3-ols and PAs, to identify potential active candidates, and to characterize their binding similarity and difference among various structures. Then, based on positive docking results, we used the M<sup>pro</sup> of SARS-Cov-2 to perform <italic>in vitro</italic> inhibitory experiments. Five compounds were identified to have anti-M<sup>pro</sup> activity. Crude extracts from green tea, cacao, chocolate, and two muscadine grapes, which are rich in flavan-3-ols and PAs, also showed inhibitory effects on the M<sup>pro</sup> activity.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and Methods</title><sec><title>Candidates of Flavan-3-ols, Flavan-3-ol Gallates, and PAs for Docking Simulation</title><p>Main flavan-3-ol aglycones include (+)-afzelechin, (&#x02013;)-epiafzelechin, (+)-catechin (CA), (&#x02013;)-epicatechin (EC), (+)-gallocatechin (GC), and (&#x02013;)-epigallocatechin (EGC). Galloylated flavan-3-ol conjugates include (&#x02013;)-epicatechin-3-O-gallate (ECG), (&#x02013;)-catechin-3-O-gallate, (&#x02013;)-gallocatechin-3-O-gallate (GCG), and (&#x02013;)-epigallocatechin-3-gallate (EGCG). Dimeric PAs include procyanidin A1, A2, B1, and B2. Fourteen structures are listed in <xref ref-type="fig" rid="F2">Figure 2</xref>. In addition, three known anti-viral medicines, ebselen, cinanserin, and lopinavir, were used as positive controls.</p></sec><sec><title>Plant Materials</title><p>Five types of plant products rich in flavan-3-ols and dimeric PAs were used for extraction. &#x0201c;<italic>Mao-Jian</italic>&#x0201d; tea is one type of top green tea (<italic>Camellia sinensis</italic>) products in China. This product is composed of newly leaves (0.8&#x02013;1.2 cm in length) of early spring sprouts (harvested around April 5 every year), which were harvested in 2019. Ripen muscadine grape berries of FLH 13-11 and FLH 17-66 were collected in 2011 and 2012, ground into powder in liquid nitrogen, freeze dried, and stored in &#x02212;80&#x000b0;C freezer (Yuzuak et al., <xref rid="B58" ref-type="bibr">2018</xref>). Cacao (<italic>Theobroma cacao</italic>) seed powder and dark chocolate used were obtained from Ecuador in 2019.</p></sec><sec><title>M<sup>pro</sup> Docking Simulation</title><p>To understand whether flavan-3-ol aglycones, flavan-3-ol gallates, and dimeric PA molecules (<xref ref-type="fig" rid="F2">Figure 2</xref>) could have anti-SARS-Cov-2 activity, we used M<sup>pro</sup> to perform docking simulation via two publically available software's websites Dock Prep tool of UCSF-Chimera (<ext-link ext-link-type="uri" xlink:href="https://www.cgl.ucsf.edu/chimera/docs">https://www.cgl.ucsf.edu/chimera/docs</ext-link>) and AutoDock vina (<ext-link ext-link-type="uri" xlink:href="http://vina.scripps.edu/">http://vina.scripps.edu/</ext-link>). In addition, three reported potential anti-COVID-19 candidate compounds, ebselen (Jin et al., <xref rid="B21" ref-type="bibr">2020a</xref>), cinanserin (Chen et al., <xref rid="B4" ref-type="bibr">2005</xref>; Jin et al., <xref rid="B21" ref-type="bibr">2020a</xref>), and lopinavir (Cao et al., <xref rid="B2" ref-type="bibr">2020</xref>), were used as positive controls for docking. We used four steps to complete docking simulation. First, we obtained a SARS-Cov-2 M<sup>pro</sup> (PDB ID: 6LU7) structure curated in the Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>), which consisted of M<sup>pro</sup> and an inhibitor N3 (<xref ref-type="fig" rid="F3">Figure 3A</xref>; Jin et al., <xref rid="B21" ref-type="bibr">2020a</xref>). Second, we used the Dock Prep tool of UCSF-Chimera to perform receptor (M<sup>pro</sup>) preparation, during which the inhibitor N3 was removed. In addition, hydrogens were added and receptor charge was optimized, which allowed determining the histidine protonation state. The resulting M<sup>pro</sup> structure file was saved in the mol2 format. Third, the 3D structures of flavan-3-ols and other interesting compounds used in this study were obtained from PubChem (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>) and used as ligands. All ligand structures were then uploaded to the Minimize structure tool of UCSF-Chimera and minimized, during which charges and hydrogens were added to each ligand. The resulting ligand files were also saved in the mol2 format. Fourth, both M<sup>pro</sup> and ligand files were uploaded to AutoDock vina for docking simulation. When we preformed simulation, based on the three dimensional model size of M<sup>pro</sup>, we used a functional tool in the software to create a grid box in a three-dimensional Cartesian coordinate space. The resulting box size was <italic>x</italic> = 50, <italic>y</italic> = 55, and <italic>z</italic> = 50 and the origin center of the box was at <italic>x</italic> = &#x02212;27, <italic>y</italic> = 13, and <italic>z</italic> = 58. The entire M<sup>pro</sup> protein was completely framed in the grid box to allow docking simulation at any locations, such as the substrate binding pocket and surface. The advantage of this complete framing was that the simulation excluded potential position bias in the selection of binding sites. Accordingly, different poses of ligands in the same binding sites could be clustered to determine the optimal binding position, which was characterized by the best docking score (affinity score). Moreover, at the optimal position, snapshots were selected to determine the ligand pose and the potential linkage such as hydrogen bond between the ligand and amino acids of M<sup>pro</sup>.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>The binding of flavan-3-ols and their gallates, procyanidin B2 and A2, and three potential anti-SARS-Cov-2 drugs to the main protease (M<sup>pro</sup>) shown by protein-ligand docking. <bold>(A)</bold> The 3D surface view of the SARS-Cov-2 M<sup>pro</sup> without and with the inhibitor peptide N3. The red rectangle frame shows the M<sup>pro</sup> substrate-binding pocket and the red amino acid residues show the N3 binding to the M<sup>pro</sup> substrate-binding pocket. <bold>(B&#x02013;F)</bold> 10 compounds bind to the M<sup>pro</sup> substrate-binding pocket, (+)-afzelechin (AF) and (&#x02013;)-epiafzelechin (EAF) <bold>(B)</bold>, (+)-catechin (CA) and (&#x02013;)-epicatechin (EPC) <bold>(C)</bold>, (+)-gallocatechin (GC) and (&#x02013;)-epigallocatechin (EGC) <bold>(D)</bold>, (&#x02013;)-gallocatechin gallate (GCG) and (&#x02013;)-epigallocatechin gallate (EGCG) <bold>(E)</bold>, and procyanidin B2 and A2 <bold>(F)</bold>. <bold>(G)</bold> Ebselen (EBS) and cinanserin (INN) bind to the M<sup>pro</sup> substrate-binding pocket. <bold>(H)</bold> Lopinavir (LOP) binds to M<sup>pro</sup> at a different position.</p></caption><graphic xlink:href="fpls-11-601316-g0003"/></fig></sec><sec><title>Extraction of Flavan-3-ols and PAs From Green Tea, Cacao, Dark Chocolate, and Muscadine Berry Powders</title><p>One gram of dry powder was suspended in 10 ml acetone: deionized water (70:30) contained in a 50 ml falcon tube. The tube was strongly vortexed for 5 min and then sonicated in a water bath for 10 min at the room temperature, followed by centrifugation at 4,000 rpm for 20 min. The resulting supernatant was pipetted to a new 50 ml tube. The remained pellet was extracted again with the same steps. Two extractions were pooled together to obtain 20 ml in volume, which was reduced to 5.0 ml by removing acetone with a nitrogen gas flow at the room temperature. The tube containing the remained water phase was added 1.0 ml chloroform and then strongly vortexed for 2.0 min, followed by centrifugation at 4,000 rpm for 5 min. The resulting lower chloroform phase containing non-polar compounds was removed. This step was repeated once. The tube that contained the remained water phase including flavan-3-ols and PAs was added 5.0 ml ethyl acetate, strongly vortexed for 3.0 min, and then centrifuged at 4,000 rpm for 5.0 min. The resulting upper ethyl acetate phase containing flavan-3-ols and PAs was transferred to a new 50 ml tube. This ethyl acetate extraction step was repeated two times. The three times of ethyl acetate extractions were pooled together and then dried completely with nitrogen flow at the room temperature. The remained residue was dissolved in DMSO to obtain 50 mg/ml extracts and stored in a &#x02212;20&#x000b0;C freezer until use.</p></sec><sec><title><italic>In vitro</italic> Inhibition Assay of M<sup>pro</sup> Activity and Calculation of IC50 Values</title><p>CA, EC, GC, EGC, CAG, GAG, ECG, EGCG, PA2, and PB2 were purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in DMSO to prepare 1.0 mM stock solution. A 3CL Protease (M<sup>pro</sup>) (SARS-CoV-2) Assay Kit (BPS bioscience, <ext-link ext-link-type="uri" xlink:href="https://bpsbioscience.com/">https://bpsbioscience.com/</ext-link>) was used to test the inhibitory activity of these 10 compounds. The steps of <italic>in vitro</italic> assay followed the manufacturer's protocol. In brief, each reaction was completed in a 25 &#x003bc;l volume in 96-well plates. Each reaction solution contains 150 ng recombinant M<sup>pro</sup> (the final concentration in the reaction, 6 ng/ &#x003bc;l), 1.0 mM DDT, 50 &#x003bc;M fluorogenic substrate, and CA, EPC, GC, EGC, CAG, GAG, ECG, EGCG, PA2, PB2 (final concentrations, 0, 0.1, 0.5, 1, 5, 10, 50, 100, 150, and 200 &#x003bc;M) or one plant extract (final concentrations, 0, 1, 10, 100, 1,000 &#x003bc;g/ml) in pH 8.0 50 mM Tris-HCl and 5.0 &#x003bc;M EDTA buffer. GC376 (50 &#x003bc;M) was used as positive control and Tris-HCl-EDTA buffer was used as negative control. The reaction mixtures were incubated for 4.0 h at the room temperature. The fluorescence intensity of each reaction was measured and recorded on a microtiter plate-reading fluorimeter (BioTek's Synergy H4 Plate Reader for detect fluorescent and luminescent signals). The excitation wavelength was 360 nm and the detection emission wavelength was 460 nm. Each concentration of compounds and extracts was tested five times. A mean value was calculated using five replicates. One-way analysis of variance (ANOVA) was performed to evaluate the statistical significance. The <italic>P</italic>-value &#x0003c; 0.05 means significant differences.</p><p>After fluorescent values were recorded, based on negative control, the fluorescent intensities of each reaction were converted to percentages, which were used to develop inhibitory effect curves with the Originlab software (<ext-link ext-link-type="uri" xlink:href="https://www.originlab.com/">https://www.originlab.com/</ext-link>). All data were imported to the Originlab workbook, which had an Analysis Toolbar including a Rank model fitting tool (a non-linear fitting tool). After data were fitted with the non-linear fitting tool, a Dose-Response Curve (DoseRes) function was used to develop non-linear regression curves. The outputs of the non-linear regression included inhibitory effect curves, standard errors, the half maximal inhibitory concentration (IC50) values and a 95% confidence interval (CI), and a range of values including IC5 with a 95% CI.</p></sec><sec><title>Evaluation of Docking Simulation With Receiver Operating Characteristic Curve</title><p>Based on actual positive and negative inhibition data obtained from <italic>in vitro</italic> assay, we used receiver operating characteristic (ROC) curve to evaluate the performance confidence of the docking simulation. To develop a ROC curve, we used &#x0201c;1&#x0201d; to stand for positives and &#x0201c;0&#x0201d; to stand for negatives. Accordingly, the sensitivity and 1-specificity false positive values were calculated for each docking score (<xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>), and then applied to the OriginLab software to create a ROC plot. Based on the obtained ROC plot, a potential cut off value for affinity score was obtained.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Docking Simulation of Compounds Binding to M<sup>pro</sup></title><p>Theoretical compound screening for inhibitors of the SARS-Cov-2 M<sup>pro</sup> is an effective approach to identify potential candidates that can be used for trials to test their inhibitory activity against SARS-Cov-2 (Xue et al., <xref rid="B57" ref-type="bibr">2008</xref>; Pillaiyar et al., <xref rid="B36" ref-type="bibr">2016</xref>; Dai W. et al., <xref rid="B6" ref-type="bibr">2020</xref>; Jin et al., <xref rid="B20" ref-type="bibr">2020b</xref>; Zhang et al., <xref rid="B59" ref-type="bibr">2020</xref>). To predict whether flavan-3-ol aglycones, their gallates, and dimeric PAs (<xref ref-type="fig" rid="F2">Figure 2</xref>) could inhibit the M<sup>pro</sup> activity, we performed docking simulation via two types of publically available software, Dock Prep tool of UCSF-Chimera and AutoDock vina. The resulting docking data showed that all flavan-3-ol aglycones, flavan-3-ol gallates, and dimeric procyanidins tested (PA2 and PB2) (<xref ref-type="fig" rid="F2">Figure 2</xref>) could bind to the same location of M<sup>pro</sup>, which is the substrate binding pocket bound by the N3 inhibitor (<xref ref-type="fig" rid="F3">Figures 3A&#x02013;F</xref>). Given that the docking simulation was completed from any positions, different poses of binding were clustered (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 1</xref>) to determine the optimal position for each ligand (<xref ref-type="fig" rid="F3">Figures 3A&#x02013;F</xref>). In addition, two antiviral control compounds, ebselen and cinanserin, bound to the same binding pocket (<xref ref-type="fig" rid="F3">Figure 3G</xref>). In contrast, the antiviral lopinavir bound to a different location (<xref ref-type="fig" rid="F3">Figure 3H</xref>).</p><p>Based on the optimal pose of ligand (<xref ref-type="fig" rid="F3">Figures 3B&#x02013;F</xref>), the affinity scores were recorded from the docking simulation. The resulting best affinity scores were &#x02212;7.0 to &#x02212;7.7 for six flavan-3-ol aglycones, &#x02212;8.3 to &#x02212;8.7 for four flavan-3-ol gallates, and &#x02212;9.2 for two dimeric proanthocyanidins (<xref rid="T1" ref-type="table">Table 1</xref>). All these scores were lower than those of ebselen and cinanserin, &#x02212;6.6 and &#x02212;5.4. The affinity scores of the dimeric PAs and flavan-3-ol-gallates were lower than &#x02212;8.0 for lopinavir. These data suggested that flavan-3-ols, flavan-3-ol gallates, and dimeric PAs were appropriate candidates with potentially inhibitory effects on the M<sup>pro</sup> activity. During our manuscript revision, a recent <italic>in silica</italic> docking for flavan-3-ols in green tea reported similar affinity score ranging from &#x02212;7.2 to 9.0 (Ghosh et al., <xref rid="B13" ref-type="bibr">2020</xref>). Another <italic>in silica</italic> docking reported the procyanidin B7 and A2 affinity scores, &#x02212;8.0 and &#x02212;8.2 (Prasanth et al., <xref rid="B37" ref-type="bibr">2020</xref>). These two studies together with ours suggest that different types of software can give similar simulation data. In addition, potential binding to other sites such as surface was observed in the docking simulation. However, compared with those promising affinity scores (<xref rid="T1" ref-type="table">Table 1</xref>) obtained from the substrate binding site, the affinity scores from other sites were bigger than &#x02212;2.0, which were insignificant for further analysis.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The affinity scores of AF, EAF, CA, EPC, GC, EGC, GCG, EGCG, PA2, and PB2 and three putative anti-COVID-19 molecules binding to the main protease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Molecules</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Affinity score</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Molecular weight</bold></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>(kcal/mol)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>(g/mol)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Procyanidin B2 (PB2)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;9.2</td><td valign="top" align="center" rowspan="1" colspan="1">578.53</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Procyanidin A2 (PA2)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;9.2</td><td valign="top" align="center" rowspan="1" colspan="1">576.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(&#x02013;)-epigallocatechin-3-O-gallate (EGCG)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;8.7</td><td valign="top" align="center" rowspan="1" colspan="1">458.37</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(&#x02013;)-gallocatechin-3-O-gallate (GCG)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;8.7</td><td valign="top" align="center" rowspan="1" colspan="1">458.37</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(&#x02013;)-epicatechin-3-O-gallate (ECG)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;8.7</td><td valign="top" align="center" rowspan="1" colspan="1">442.37</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(+)-catechin-3-O-gallate (CAG)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;8.3</td><td valign="top" align="center" rowspan="1" colspan="1">442.37</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(&#x02013;)-epigallocatechin (EGC)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.7</td><td valign="top" align="center" rowspan="1" colspan="1">306.27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(+)-gallocatechin (GC)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.6</td><td valign="top" align="center" rowspan="1" colspan="1">306.27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(&#x02013;)-epicatechin (EPC)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.5</td><td valign="top" align="center" rowspan="1" colspan="1">290.27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(+)-catechin (CA)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.5</td><td valign="top" align="center" rowspan="1" colspan="1">290.27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(&#x02013;)-epiafzelechin (EAF)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.5</td><td valign="top" align="center" rowspan="1" colspan="1">274.26</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(&#x02013;)-afzelechin (AF)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.0</td><td valign="top" align="center" rowspan="1" colspan="1">274.26</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lopinavir (LOP)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;8.0</td><td valign="top" align="center" rowspan="1" colspan="1">628.81</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ebselen (EBS)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;6.6</td><td valign="top" align="center" rowspan="1" colspan="1">274.17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cinanserin (CIN)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;5.4</td><td valign="top" align="center" rowspan="1" colspan="1">340.49</td></tr></tbody></table></table-wrap></sec><sec><title>Spatial Binding Characteristics at Different Subsites of M<sup>pro</sup></title><p>The substrate binding pocket of M<sup>pro</sup> has four subsites, S1&#x02032;, S1, S2, and S4 (Dai W. et al., <xref rid="B6" ref-type="bibr">2020</xref>). Substrate-binding analysis was completed for ebselen (positive control) and 14 compounds (<xref ref-type="fig" rid="F2">Figure 2</xref>). The results predicted different binding features among ebselen, six flavan-3-ol aglycones, four flavan-3-ol-gallates, and two dimeric PAs. The two benzene rings of ebselen were predicted to face to S1 and S1&#x02032; (<xref ref-type="fig" rid="F4">Figure 4A</xref>), while the 14 compounds were predicted to face to three or four subsites (<xref ref-type="fig" rid="F4">Figures 4B&#x02013;E</xref>). The A-ring and B-ring of EGC were predicted to face to S2/S4 and S1, respectively (<xref ref-type="fig" rid="F4">Figure 4B</xref>). The same patterns were predicted for AF, EAF, CA, EPC, and GC. The A-ring, B-ring, and the gallate ester group of EGCG were predicted to face to S2, S1&#x02032;, and S1, respectively (<xref ref-type="fig" rid="F4">Figure 4C</xref>). The same patterns were obtained for CAG, ECG, and GCG. In the PA1 and PA2 binding, the A-ring and B-ring of the starter unit and the B-ring of the upper unit were predicted to face to S1, S4, and S1&#x02032;, respectively (<xref ref-type="fig" rid="F4">Figure 4D</xref>). In PB1 and B2 docking modeling, the B-ring of the starter unit and the A-ring and B-ring of upper unit were predicted to face to S1&#x02032;, S1, and S2, respectively (<xref ref-type="fig" rid="F4">Figure 4E</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Features of ebselen, (&#x02013;)-epigallocatechin, (&#x02013;)-epigallocatechin 3-O-gallate (EGCG), procyanidin A2 (PA2), and procyanidin B2 (PB2) binding to subsites in M<sup>pro</sup> predicted by protein-ligand docking modeling. <bold>(A)</bold> Ebselen binds to S1 and S1&#x02032; subsites. <bold>(B)</bold> (&#x02013;)-epigallocatechin binds to S1, S2/S4 subsites of the M<sup>pro</sup>. <bold>(C)</bold> (&#x02013;)-epigallocatechin 3-O-gallate binds to the S1, S1&#x02032;, and S2 subsites of M<sup>pro</sup>, <bold>(D)</bold> procyanidin A2 binds to the S1&#x02032;, S1, and S4 subsites of M<sup>pro</sup>. <bold>(E)</bold> Procyanidin B2 binds to the S1, S1&#x02032;, and S2 subsites of M<sup>pro</sup>.</p></caption><graphic xlink:href="fpls-11-601316-g0004"/></fig></sec><sec><title>Potential Hydrogen Bonds Formed Between Compounds and the Binding Pocket of M<sup>pro</sup></title><p>This docking simulation predicted that the binding of these compounds to the substrate binding pocket was via the formation of hydrogen bonds. Based on the best affinity score of each compound (<xref rid="T1" ref-type="table">Table 1</xref>), the docking simulation could predict the most potential hydrogen bonds formed between each compound and the binding pocket of M<sup>pro</sup>. The resulting data showed different features of the hydrogen bond number and potential linkage positions between compounds and amino acids of M<sup>pro</sup> (<xref ref-type="fig" rid="F5">Figures 5A&#x02013;J</xref>). Three hydrogen bonds were predicted to be formed between AF, EAF, CA, or EC and M<sup>pro</sup> (<xref ref-type="fig" rid="F5">Figures 5A&#x02013;D</xref>). The linkages of those three hydrogen bonds were formed between AF and M<sup>pro</sup> via O<sub>1</sub>-Glu<sub>166</sub>, C<sub>3</sub>-O-Glu<sub>166</sub>, and C<sub>7</sub>-O-Leu<sub>141</sub> (<xref ref-type="fig" rid="F5">Figure 5A</xref>), between EAF and M<sup>pro</sup> via O<sub>1</sub>-Glu<sub>166</sub>, C<sub>7</sub>-O-Leu<sub>141</sub>, and C<sub>4&#x02032;</sub>-O-Gln<sub>189</sub> (<xref ref-type="fig" rid="F5">Figure 5B</xref>), between CA and M<sup>pro</sup> via O<sub>1</sub>-Glu<sub>166</sub>, C<sub>3</sub>-O-Glu<sub>166</sub>, and C<sub>4&#x02032;</sub>-O-Leu<sub>141</sub> (<xref ref-type="fig" rid="F5">Figure 5C</xref>), and between EC and M<sup>pro</sup> via O<sub>1</sub>-Glu<sub>166</sub>, C<sub>7</sub>-O-Thr<sub>190</sub>, and C<sub>4&#x02032;</sub>-O-Gln<sub>189</sub> (<xref ref-type="fig" rid="F5">Figure 5D</xref>). GC, EGC, and GCG were predicted to form one hydrogen bond with M<sup>pro</sup> via O<sub>1</sub>-Glu<sub>166</sub> (<xref ref-type="fig" rid="F5">Figures 5E&#x02013;G</xref>). EGCG and M<sup>pro</sup> were predicted to form four hydrogen bonds via O<sub>1</sub>-Glu<sub>166</sub>, C<sub>7</sub>-O-Thr<sub>190</sub>, C<sub>5&#x02032;</sub>-O-Phe<sub>140</sub>, and gallate-3-O-Gly<sub>143</sub> (<xref ref-type="fig" rid="F5">Figure 5H</xref>). PA2 and M<sup>pro</sup> were predicted to form one hydrogen bond via C<sub>3&#x02032;</sub>-O-Gly<sub>143</sub>. PB2 and M<sup>pro</sup> were predicted to form three hydrogen bonds via C<sub>5&#x02032;</sub>-O-Gly<sub>143</sub> and C<sub>5&#x02032;</sub>-O-Cys<sub>145</sub> on the B ring of the upper unit and C<sub>3</sub>-O-Glu<sub>166</sub> on the C-ring of the starter unit. Furthermore, all hydrogen-binding distances were different from 1.833&#x000c5; between PA2 and M<sup>pro</sup> (<xref ref-type="fig" rid="F5">Figure 5I</xref>) to 2.541 &#x000c5; between EGC and M<sup>pro</sup> (<xref ref-type="fig" rid="F5">Figure 5F</xref>).</p><fig id="F5" position="float"><label>Figure 5</label><caption><p>Potential hydrogen bonds formed between M<sup>pro</sup> and 10 compounds predicted by ligand-protein modeling. These bond positions and numbers formed between 10 various metabolites and the binding pocket of M<sup>pro</sup> were predicted based on the best affinity scores of each compound (<xref rid="T1" ref-type="table">Table 1</xref>). (+)-afzelechin (AF) <bold>(A)</bold>, (&#x02013;)-epiafzelechin <bold>(B)</bold>, (+)-catechin (CA) <bold>(C)</bold>, and (&#x02013;)-epicatechin <bold>(D)</bold> were predicted form three hydrogen bonds with M<sup>pro</sup>. The hydrogen patterns were the same between AF and CA, while those were the same between EAF and EC. (+)-Gallocatechin <bold>(E)</bold>, (&#x02013;)-epigallocatechin <bold>(F)</bold>, and (&#x02013;)-gallocatechin gallate <bold>(G)</bold> were predicted to form one hydrogen with M<sup>pro</sup>. <bold>(H)</bold> (&#x02013;)-epigallocatechin gallate was predicted to form three hydrogen bonds with M<sup>pro</sup>. Procyanidin A2 <bold>(I)</bold> and B2 <bold>(J)</bold> were predicted to form one and three hydrogen bonds with M<sup>pro</sup>.</p></caption><graphic xlink:href="fpls-11-601316-g0005"/></fig></sec><sec><title><italic>In vitro</italic> Inhibitory Effects of 10 Compounds on the M<sup>pro</sup> Activity</title><p>To understand the effects of these docking promising compounds on the M<sup>pro</sup> activity, we used CA, EPC, GC, EGC, CAG, ECG, GCG, EGCG, PA2, and PB2 to perform <italic>in vitro</italic> inhibition assay. The resulting inhibitory curves showed that CAG, ECG, GCG, EGCG, and PB2 inhibited the M<sup>pro</sup> activity (<xref ref-type="fig" rid="F6">Figure 6</xref>). The values of the half maximal inhibitory concentration (IC<sub>50</sub>) for CAG, ECG, GCG, EGCG, and PB2 were ~2.98 &#x000b1; 0.21, 5.21 &#x000b1; 0.5, 6.38 &#x000b1; 0.5, 7.51 &#x000b1; 0.21, and 75.3 &#x000b1; 1.29 &#x003bc;M, respectively (<xref ref-type="fig" rid="F6">Figures 6A&#x02013;E</xref>). The resulting data showed when the concentrations of these compounds were increased, such as 100 &#x003bc;M, the inhibition of PB2 was more effective than that of CAG, GCG, and EGCG (<xref ref-type="fig" rid="F6">Figure 6F</xref>). In contrast, the <italic>in vitro</italic> analysis did not detect that CA, EPC, GC, EGC, and PA2 in a range of concentrations from 0 to 500 &#x003bc;M tested could inhibit the M<sup>pro</sup> activity (<xref ref-type="fig" rid="F6">Figure 6F</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Figures 2A&#x02013;E</xref>).</p><fig id="F6" position="float"><label>Figure 6</label><caption><p>Inhibitory effects of four flavan-3-ol-gallates, four flavan-3-ol aglycones, procyanidin A2 (PA2), and procyanidin B2 (PB2) on the M<sup>pro</sup> activity of SARS-COv-2. Inhibitory curves show that (+)-catechin-3-O-gallate (CAG) <bold>(A)</bold>, (&#x02013;)-epicatechin-3-O-gallate (ECG) <bold>(B)</bold>, (&#x02013;)-gallocatechin-3-O-gallate (GCG) <bold>(C)</bold>, (&#x02013;)-epigallocatechin-3-O-gallate (EGCG) <bold>(D)</bold>, and PB2 <bold>(E)</bold> inhibit the activity of M<sup>pro</sup> with an IC<sub>50</sub> 2.98 &#x000b1; 0.21 &#x003bc;M, IC<sub>50</sub> 5.21 &#x000b1; 0.5 &#x003bc;M, IC<sub>50</sub> 6.38 &#x000b1; 0.5 &#x003bc;M, IC<sub>50</sub> 7.51 &#x000b1; 0.21 &#x003bc;M, and IC<sub>50</sub> 75.31 &#x000b1; 1.29 &#x003bc;M, respectively. <bold>(F)</bold> Inhibitory effects of 100 &#x003bc;M (&#x02013;)-epicatechin (EC), (+)-catechin (CA), EGC, CAG, ECG, GCG, EGCG, PA2, and PB2 on the activity of M<sup>pro</sup>. Compared with the negative control, the activity of M<sup>pro</sup> is inhibited by 40, 40, 44.4, 50, 81.5, and 100% by 100 &#x003bc;M CAG, ECG, EGCG, GCG, PB2, and positive control GC376. 95% CI: 95% confidence internal and (value 1, value 2): values in the range with 95% CI.</p></caption><graphic xlink:href="fpls-11-601316-g0006"/></fig></sec><sec><title>Evaluation With Receiver Operating Characteristic Curve</title><p>Based on <italic>in vitro</italic> assay, a receiver operating characteristic (ROC) curve was established to evaluate the performance confidence of the docking simulation. <italic>In vitro</italic> inhibition data and affinity scores were used to calculate sensitivity and 1-specificity positive values (<xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>), which were used to establish a ROC curve. The resulting plot showed that the area under the ROC (AUROC) was 0.8864 (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 3</xref>), indicating an excellent performance of the docking simulation. The resulting data indicated that the docking scores higher than &#x02212;7.6 could be used to predict the non-inhibition of flavan-3-ol aglycones against the M<sup>pro</sup> activity. On other hand, except for PA2, the docking scores lower than &#x02212;8.3 could be used to predict the inhibition of flavan-3-ol conjugates and dimers against the M<sup>pro</sup> activity. Accordingly, this ROC evaluation indicated that the docking simulation was appropriate in predicting the inhibitory activity of flavan-3-ols and their conjugates and dimers.</p></sec><sec><title><italic>In vitro</italic> Inhibitory Effects of Plant Extracts on the M<sup>pro</sup> Activity</title><p>Green tea (Zhao et al., <xref rid="B60" ref-type="bibr">2017</xref>; Wang P. et al., <xref rid="B50" ref-type="bibr">2020</xref>), two muscadine grape cultivar berries (including seeds and skin) (Yuzuak et al., <xref rid="B58" ref-type="bibr">2018</xref>), and dark chocolate and cacao (Takahashi et al., <xref rid="B46" ref-type="bibr">1999</xref>; Schewe et al., <xref rid="B41" ref-type="bibr">2001</xref>) are rich in flavan-3-ol gallates and dimeric PAs. To understand whether these plant products could inhibit the M<sup>pro</sup> activity of SARS-Cov-2, we extracted flavan-3-ol gallates and dimeric PAs from the five types of materials and then completed <italic>in vitro</italic> assays. The resulting data showed that all extracts of these products could inhibit the M<sup>pro</sup> activity (<xref ref-type="fig" rid="F7">Figures 7A&#x02013;F</xref>). The green tea extracts showed the highest inhibitory activity with an IC<sub>50</sub> 2.84 &#x000b1; 0.25 &#x003bc;g/ml. At 10 &#x003bc;g/ml, the green tea extract tea completely inhibited the M<sup>pro</sup> activity (<xref ref-type="fig" rid="F7">Figure 7A</xref>). In recent, we reported that green tea extracts contained a high content of EGCG, a relatively high content of ECG, and appropriate contents of dimeric procyanidin B1, B2, B3, and B4 (Zhao et al., <xref rid="B60" ref-type="bibr">2017</xref>; Dai X. et al., <xref rid="B7" ref-type="bibr">2020</xref>; Wang P. et al., <xref rid="B50" ref-type="bibr">2020</xref>). Thus, the inhibitory activity of green tea extracts resulted from these compounds. The extracts of two muscadine grapes FLH 13-11 and FLH17-66 inhibited the M<sup>pro</sup> activity with an IC<sub>50</sub> 29.54 &#x000b1; 0.41 &#x003bc;g/ml and an IC<sub>50</sub> 29.93 &#x000b1; 0.83 &#x003bc;g/ml. At 100 &#x003bc;g/ml, the extracts of two muscadine grapes completely inhibited the M<sup>pro</sup> activity (<xref ref-type="fig" rid="F7">Figures 7B&#x02013;F</xref>). In recent, we also reported that extracts of these two muscadine cultivar berries contained EGCG, ECG, and procyanidin B1-B3 and B5-B8 (Yuzuak et al., <xref rid="B58" ref-type="bibr">2018</xref>). The inhibitory activity of the muscadine extracts was associated with the presence of these compounds. Cacao and dark chocolate extracts were shown to inhibit the M<sup>pro</sup> activity when the extract concentrations tested were higher than 10 &#x003bc;g/ml and their IC<sub>50</sub> values were 153.3 &#x000b1; 47.3 &#x003bc;g/ml and 256.39 &#x000b1; 66.3 &#x003bc;g/ml, respectively (<xref ref-type="fig" rid="F7">Figures 7D,E</xref>). Given that ECG, EGCG, and PB2 were characterized to be main plant flavonoids in the cacao and dark chocolate extracts (Takahashi et al., <xref rid="B46" ref-type="bibr">1999</xref>; Schewe et al., <xref rid="B41" ref-type="bibr">2001</xref>), the inhibitory activity of these two extracts resulted from these compounds. We further compared the inhibitory activity of all extracts at 100 &#x003bc;g/ml tested, the results showed that the extracts of green tea and two muscadine grapes completely inhibited the M<sup>pro</sup> activity and the extracts of cacao and dark chocolate reduced the M<sup>pro</sup> activity by 40&#x02013;50% (<xref ref-type="fig" rid="F7">Figure 7F</xref>).</p><fig id="F7" position="float"><label>Figure 7</label><caption><p>Inhibitory effects of five extracts on the M<sup>pro</sup> activity. <bold>(A&#x02013;E)</bold> Curves show inhibitory activities of different concentrations of extracts from green tea with an IC<sub>50</sub> 2.84 &#x000b1; 0.25 &#x003bc;g/ml <bold>(A)</bold>, FLH13-11 muscadine berry with an IC50 29.54 &#x000b1; 0.41 &#x003bc;g/ml <bold>(B)</bold>, FLH17-66 berry with an IC<sub>50</sub> 29.93 &#x000b1; 0.83 &#x003bc;g/ml <bold>(C)</bold>, cacao with an IC<sub>50</sub> 153.3 &#x000b1; 47.3 &#x003bc;g/ml <bold>(D)</bold>, and dark chocolate with an IC<sub>50</sub> 256.39 &#x000b1; 66.3 &#x003bc;g/ml <bold>(E)</bold>. <bold>(F)</bold> Inhibition of the M<sup>pro</sup> activity by 100 &#x003bc;g/ml extracts of green tea, cacao, chocolate, FLH13-11 muscadine berry, and FLH17-66 muscadine berry. GC376 (100 &#x003bc;g/ml) and 1% DMSO in water were used as positive and negative controls. All values are averaged from five replicates. 95% CI: 95% confidence internal and (value 1, value 2): values in the range with 95% CI.</p></caption><graphic xlink:href="fpls-11-601316-g0007"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Both docking simulation and <italic>in vitro</italic> assays showed that the stereo configurations, galloylation, and oligomeric types of flavan-3-ols affected the ligand-protein binding features and inhibitory activity. Flavan-3-ols and PAs are two groups of plant flavonoids (Xie and Dixon, <xref rid="B56" ref-type="bibr">2005</xref>). PAs are oligomeric or polymeric flavan-3-ols. Flavan-3-ol aglycones have four different stereo configurations at C<sub>2</sub> and C<sub>3</sub> on the C-ring (<xref ref-type="fig" rid="F2">Figure 2</xref>). For example, (+)-catechin at C<sub>2</sub> and C<sub>3</sub> has a <italic>2R, 3S</italic>-2, 3-<italic>trans</italic> configuration (<xref ref-type="fig" rid="F2">Figure 2</xref>). Its isomer (&#x02013;)-epicatechin has a <italic>2R, 3R</italic>-2, 3-<italic>cis</italic> configuration. (&#x02013;)-Catechin and (+)-epicatechin have a <italic>2S, 3R</italic>-2, 3-<italic>trans</italic> and a <italic>2S, 3S</italic>-2, 3-<italic>cis</italic> configuration, respectively (Xie and Dixon, <xref rid="B56" ref-type="bibr">2005</xref>). In addition, the number of hydroxyl groups on the B-ring, such as one on AF, two on CA, and three on GA (<xref ref-type="fig" rid="F2">Figure 2</xref>), diversifies structures. To understand whether these stereo configurations and the hydroxyl group numbers can affect docking simulation and be associated with inhibitory activity, we screened and tested representative flavan-3-ol aglycones, flavan-3-ol gallates, and dimeric PAs. Six flavan-3-ol aglycones included AF, EAF, CA, EC, GC, and EGC (<xref ref-type="fig" rid="F2">Figure 2</xref>), which represented three types of hydroxyl group numbers on the B-ring and two types of stereo configurations at C<sub>2</sub> and C<sub>3</sub>. All six compounds were predicted to be able to bind to the binding pocket of M<sup>pro</sup> (<xref ref-type="fig" rid="F3">Figure 3</xref>). It was interesting that the affinity scores decreased as the number of hydroxyl groups on the B-ring of flavan-3-ols increased (<xref rid="T1" ref-type="table">Table 1</xref>). This datum indicates that more hydroxyl groups on the B-ring increase the binding capacity to M<sup>pro</sup>. Furthermore, the docking simulation showed that the galloylation at C<sub>3</sub>-OH of CA, EC, GC, and EGC and dimerization of EC decreased the affinity scores (<xref rid="T1" ref-type="table">Table 1</xref>), indicating that the galloylation and oligomerization could increase the binding capacity to M<sup>pro</sup>. Meanwhile, the galloylation of flavan-3-ols increases the acidity of flavan-3-ols and their molecular weights (<xref rid="T1" ref-type="table">Table 1</xref>). These chemical feature changes might also be associated the increased binding capacity. Based on the docking simulation and affinity scores, we hypothesized that 12 compounds (<xref ref-type="fig" rid="F2">Figure 2</xref>) could have an inhibitory activity against the M<sup>pro</sup> activity. However, in <italic>vitro</italic> assays only detected the positively inhibitory effects of galloylated flavan-3-ols, including CAG, ECG, GCG, and EGCG, on the M<sup>pro</sup> activity (<xref ref-type="fig" rid="F6">Figure 6</xref>). No inhibitory activity was detected in the assays of CA, EC, GC, and EGC (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 2</xref>), although their affinity scores were from &#x02212;7.5 to &#x02212;7.7. These data indicate that although positive docking data are useful to screen candidates, <italic>in vitro</italic> test experiments are necessary to show an activity. Furthermore, these data showed that the galloylation of these flavan-3-ols created the inhibitory activity against M<sup>&#x000b0;<italic>ro</italic></sup>. In addition, it was interesting that although the affinity scores of PA2 and PB2 were the same, &#x02212;9.2, PB2 but not PA2 showed an inhibitory activity against M<sup>&#x000b0;<italic>ro</italic></sup> (<xref ref-type="fig" rid="F6">Figure 6E</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 2</xref>). This datum indicates that the dimeric PA types are closely associated with the inhibitory activities. Based on these <italic>in vitro</italic> assay data and affinity scores, a ROC curve was developed to evaluate the performance confidence of docking simulations for screening flavan-3-ols and PAs (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 3</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>). Although only 12 compounds were screened with docking simulation and 10 compounds were tested <italic>in vitro</italic>, the resulting ROC curve could provide a promising prediction. Based on the ROC curve, the affinity score &#x02212;8.3 could be proposed to be a cut off value to screen flavan-3-ol derivatives for anti-SARS-Cov-2 candidates.</p><p>Although it was difficult to test more flavan-3-ol gallates and dimeric PAs due to the unavailability of compounds, we could take advantage of natural sources to understand the inhibitory effects of more flavan-3-ol gallates and dimeric PAs on the M<sup>pro</sup> activity. Our previous UPLC-MS based profiling showed that that green tea (GT) produced not only EGCG and PB2 but also ECG, GCG, CAG, procyanidin B1 (PB1), PB3, and PB4 (Zhao et al., <xref rid="B60" ref-type="bibr">2017</xref>; Dai X. et al., <xref rid="B7" ref-type="bibr">2020</xref>; Wang P. et al., <xref rid="B50" ref-type="bibr">2020</xref>). We prepared extracts from GT and tested their activity. The resulting inhibitory activity was effective and the concentration at 10 &#x003bc;g/ml could completely inhibit the M<sup>pro</sup> activity (<xref ref-type="fig" rid="F7">Figure 7A</xref>). These data suggest that in addition to ECG, GCG, CAG, EGCG, and PB2 tested, PB1, PB3, and PB4 may provide additive inhibitory activity against the M<sup>pro</sup> activity. In addition, our recent HPLC-MS/MS based profiling reported that the berries (including seeds and peels) of two muscadine grape cultivars, FLH 13-11 FL and FLH 17-66 FL, produced four flavan-3-ol aglycones, 18 galloylated or glycosylated conjugates, and eight dimeric procyanidins (Yuzuak et al., <xref rid="B58" ref-type="bibr">2018</xref>). The extracts of these two muscadine grapes showed an effective inhibitory activity against the M<sup>pro</sup> activity (<xref ref-type="fig" rid="F7">Figures 7B,C</xref>), indicating that those untested dimeric PAs and flavan-3-ol conjugates might enhance the inhibitory activity. We recently analyzed cacao nut and DW extracts and identified PB1 and PB2 in the extracts. These two extracts also showed appropriately inhibitory activity against the M<sup>pro</sup> activity. Based on these flavan-3-ol, flavan-3-ol gallate, and dimeric PA-containing natural resources, we hypothesize that those flavan-3-ol gallates, dimeric PAs, and oligomeric PAs untested have inhibitory effects on the M<sup>pro</sup> activity. Besides, we anticipate that it is valuable to continuously screen more flavan-3-ol gallates and other derivatives as well as PAs, from which effective compounds can be identified for anti-SARS-Cov-2 efforts. In summary, although these natural extracts have not been tested for the inhibitory efficacy in animals and humans, based on their inhibitory activity <italic>in vitro</italic>, we propose that an increased consumption of these common products can enhance preventing against SARS-Cov-2 and improving the COVID-19.</p><p>Conclusion, both docking simulation and <italic>in vitro</italic> assay showed that (&#x02013;)-catechin-3-O-gallate (7), (&#x02013;)-epicatechin-3-O-gallate (8), (&#x02013;)-gallocatechin-3-O-gallate (9), and (&#x02013;)-epigallocatechin-3-O-gallate (10), procyanidin B1 (11) and B2 (12) inhibited the M<sup>pro</sup> activity of SARS-Cov-2. Moreover, these compound-rich extracts of green tea, muscadine grape, cacao, and dark chocolate also inhibited the M<sup>pro</sup> activity. Given that there is not an effective medicine for the treatment of COVID-19 and not a vaccine for preventing against the SARS-Cov-2 infection and transmission, these data recommend that these nutraceutical compounds and extracts of green tea, grape, and cacao can be utilized to interfere the devastation of SARS-Cov-2.</p></sec><sec sec-type="data-availability" id="s5"><title>Data Availability Statement</title><p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>.</p></sec><sec id="s6"><title>Author Contributions</title><p>D-YX perceived and supervised the entire project, prepared figures, drafted, and finalized the manuscript. YZ completed docking analysis, completed experiments, prepared figures, and drafted materials, methods, and results. Both authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>We are grateful to our Borlaug Fellow, Dr. Maria Elena Cazar from Universidad de Cuenca, Ecuador, for kindly providing us cacao powder and dark chocolate.</p></ack><sec sec-type="supplementary-material" id="s7"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fpls.2020.601316/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fpls.2020.601316/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Data_Sheet_1.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akagi</surname><given-names>T.</given-names></name><name><surname>Ikegami</surname><given-names>A.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Yoshida</surname><given-names>J.</given-names></name><name><surname>Yamada</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Expression balances of structural genes in shikimate and flavonoid biosynthesis cause a difference in proanthocyanidin accumulation in persimmon (<italic>Diospyros kaki</italic> Thunb.) fruit</article-title>. <source>Planta</source>
<volume>230</volume>, <fpage>899</fpage>&#x02013;<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1007/s00425-009-0991-6</pub-id><?supplied-pmid 19669159?><pub-id pub-id-type="pmid">19669159</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume>, <fpage>1787</fpage>&#x02013;<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2008043</pub-id><?supplied-pmid 32187464?><pub-id pub-id-type="pmid">32187464</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavarria-Mir&#x000f3;</surname><given-names>G.</given-names></name><name><surname>Anfruns-Estrada</surname><given-names>E.</given-names></name><name><surname>Guix</surname><given-names>S.</given-names></name><name><surname>Paraira</surname><given-names>M.</given-names></name><name><surname>Galofr&#x000e9;</surname><given-names>B</given-names></name><name><surname>S&#x000e1;anchez</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Sentinel surveillance of SARS-CoV-2 in wastewater anticipates the occurrence of COVID-19 cases</article-title>. <source>medRxiv. [Preprint]</source>. <pub-id pub-id-type="doi">10.1101/2020.06.13.20129627</pub-id><?supplied-pmid 32425251?><pub-id pub-id-type="pmid">32425251</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Gui</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name><name><surname>Scandella</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication <italic>in vitro</italic></article-title>. <source>J. Virol.</source>
<volume>79</volume>, <fpage>7095</fpage>&#x02013;<lpage>7103</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.11.7095-7103.2005</pub-id><?supplied-pmid 15890949?><pub-id pub-id-type="pmid">15890949</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Rolain</surname><given-names>J.-M.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Chloroquine for the 2019 novel coronavirus SARS-CoV-2</article-title>. <source>Int. J. Antimicrob. Agents</source>
<volume>55</volume>, <fpage>105923</fpage>&#x02013;<lpage>105923</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105923</pub-id><pub-id pub-id-type="pmid">32070753</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>X.-M.</given-names></name><name><surname>Su</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease</article-title>. <source>Science</source>
<volume>368</volume>, <fpage>1331</fpage>&#x02013;<lpage>1335</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb4489</pub-id><?supplied-pmid 32321856?><pub-id pub-id-type="pmid">32321856</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhuang</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Discovery and characterization of tannase genes in plants: roles in hydrolysis of tannins</article-title>. <source>New Phytol.</source>
<volume>226</volume>, <fpage>1104</fpage>&#x02013;<lpage>1116</lpage>. <pub-id pub-id-type="doi">10.1111/nph.16425</pub-id><?supplied-pmid 32061142?><pub-id pub-id-type="pmid">32061142</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bruyne</surname><given-names>T.</given-names></name><name><surname>Pieters</surname><given-names>L.</given-names></name><name><surname>Witvrouw</surname><given-names>M.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>vanden Berghe</surname><given-names>D.</given-names></name><name><surname>Vlietinck</surname><given-names>A. J.</given-names></name></person-group> (<year>1999</year>). <article-title>Biological evaluation of proanthocyanidin dimers and related polyphenols</article-title>. <source>J. Nat. Prod.</source>
<volume>62</volume>, <fpage>954</fpage>&#x02013;<lpage>958</lpage>. <pub-id pub-id-type="doi">10.1021/np980481o</pub-id><?supplied-pmid 10425115?><pub-id pub-id-type="pmid">10425115</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>T. C.</given-names></name><name><surname>Mirbeth</surname><given-names>B.</given-names></name><name><surname>Rentsch</surname><given-names>J.</given-names></name><name><surname>Sutter</surname><given-names>C.</given-names></name><name><surname>Ring</surname><given-names>L.</given-names></name><name><surname>Flachowsky</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Premature and ectopic anthocyanin formation by silencing of anthocyanidin reductase in strawberry (<italic>Fragaria x ananassa</italic>)</article-title>. <source>New Phytol.</source>
<volume>201</volume>, <fpage>440</fpage>&#x02013;<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1111/nph.12528</pub-id><?supplied-pmid 24117941?><pub-id pub-id-type="pmid">24117941</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foo</surname><given-names>L. Y.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Howell</surname><given-names>A. B.</given-names></name><name><surname>Vorsa</surname><given-names>N.</given-names></name></person-group> (<year>2000a</year>). <article-title>The structure of cranberry proanthocyanidins which inhibit adherence of uropathogenic P-fimbriated <italic>Escherichia coli in vitro</italic></article-title>. <source>Phytochemistry</source>
<volume>54</volume>, <fpage>173</fpage>&#x02013;<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9422(99)00573-7</pub-id><?supplied-pmid 10872208?><pub-id pub-id-type="pmid">10872208</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foo</surname><given-names>L. Y.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Howell</surname><given-names>A. B.</given-names></name><name><surname>Vorsa</surname><given-names>N.</given-names></name></person-group> (<year>2000b</year>). <article-title>A-type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated <italic>Escherichia coli</italic></article-title>. <source>J. Nat. Prod.</source>
<volume>63</volume>, <fpage>1225</fpage>&#x02013;<lpage>1228</lpage>
<pub-id pub-id-type="doi">10.1021/np000128u</pub-id><?supplied-pmid 11000024?><pub-id pub-id-type="pmid">11000024</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fossen</surname><given-names>T.</given-names></name><name><surname>Rayyan</surname><given-names>S.</given-names></name><name><surname>Andersen</surname><given-names>O. M.</given-names></name></person-group> (<year>2004</year>). <article-title>Dimeric anthocyanins from strawberry (<italic>Fragaria ananassa</italic>) consisting of pelargonidin 3-glucoside covalently linked to four flavan-3-ols</article-title>. <source>Phytochemistry</source>
<volume>65</volume>, <fpage>1421</fpage>&#x02013;<lpage>1428</lpage>. <pub-id pub-id-type="doi">10.1016/j.phytochem.2004.05.003</pub-id><?supplied-pmid 15231416?><pub-id pub-id-type="pmid">15231416</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>R.</given-names></name><name><surname>Chakraborty</surname><given-names>A.</given-names></name><name><surname>Biswas</surname><given-names>A.</given-names></name><name><surname>Chowdhuri</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study</article-title>. <source>J. Biomol. Struct. Dyn.</source>
<fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1779818</pub-id><?supplied-pmid 32568613?><pub-id pub-id-type="pmid">32568613</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Kelm</surname><given-names>M.</given-names></name><name><surname>Hammerstone</surname><given-names>J. F.</given-names></name><name><surname>Beecher</surname><given-names>G.</given-names></name><name><surname>Cunningham</surname><given-names>D.</given-names></name><name><surname>AVAnnozzi</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Fractionation of polymeric procyanidins from lowbush blueberry and quantification of procyanidins in selected foods with an optimized normal-phase HPLC-MS fluorescent detection method</article-title>. <source>J. Agric. Food Chem.</source>
<volume>50</volume>, <fpage>4852</fpage>&#x02013;<lpage>4860</lpage>
<pub-id pub-id-type="doi">10.1021/jf020214v</pub-id><?supplied-pmid 12166971?><pub-id pub-id-type="pmid">12166971</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helms</surname><given-names>J.</given-names></name><name><surname>Kremer</surname><given-names>S.</given-names></name><name><surname>Merdji</surname><given-names>H.</given-names></name><name><surname>Clere-Jehl</surname><given-names>R.</given-names></name><name><surname>Schenck</surname><given-names>M.</given-names></name><name><surname>Kummerlen</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Neurologic features in severe SARS-CoV-2 infection</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume>, <fpage>2268</fpage>&#x02013;<lpage>2270</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2008597</pub-id><pub-id pub-id-type="pmid">32294339</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>M&#x000f6;sbauer</surname><given-names>K.</given-names></name><name><surname>Hofmann-Winkler</surname><given-names>H.</given-names></name><name><surname>Kaul</surname><given-names>A.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2</article-title>. <source>Nature</source>
<volume>585</volume>, <fpage>588</fpage>&#x02013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2575-3</pub-id><?supplied-pmid 32698190?><pub-id pub-id-type="pmid">32698190</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>A. B.</given-names></name><name><surname>Reed</surname><given-names>J. D.</given-names></name><name><surname>Krueger</surname><given-names>C. G.</given-names></name><name><surname>Winterbottom</surname><given-names>R.</given-names></name><name><surname>Cunningham</surname><given-names>D. G.</given-names></name><name><surname>Leahy</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity</article-title>. <source>Phytochemistry</source>
<volume>66</volume>, <fpage>2281</fpage>&#x02013;<lpage>2291</lpage>
<pub-id pub-id-type="doi">10.1016/j.phytochem.2005.05.022</pub-id><?supplied-pmid 16055161?><pub-id pub-id-type="pmid">16055161</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacopini</surname><given-names>P.</given-names></name><name><surname>Baldi</surname><given-names>M.</given-names></name><name><surname>Storchi</surname><given-names>P.</given-names></name><name><surname>Sebastiani</surname><given-names>L.</given-names></name></person-group> (<year>2008</year>). <article-title>Catechin, epicatechin, quercetin, rutin and resveratrol in red grape: content, <italic>in vitro</italic> antioxidant activity and interactions</article-title>. <source>J. Food Compos. Anal.</source>
<volume>21</volume>, <fpage>589</fpage>&#x02013;<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1016/j.jfca.2008.03.011</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasawa</surname><given-names>A.</given-names></name><name><surname>Niwano</surname><given-names>Y.</given-names></name><name><surname>Mokudai</surname><given-names>T.</given-names></name><name><surname>Kohno</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Antiviral activity of proanthocyanidin against feline calicivirus used as a surrogate for noroviruses, and coxsackievirus used as a representative enteric virus</article-title>. <source>Biocontrol. Sci.</source>
<volume>14</volume>, <fpage>107</fpage>&#x02013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.4265/bio.14.107</pub-id><?supplied-pmid 19785283?><pub-id pub-id-type="pmid">19785283</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020b</year>). <article-title>Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur</article-title>. <source>Nat. Struct. Mol. Biol.</source>
<volume>27</volume>, <fpage>529</fpage>&#x02013;<lpage>532</lpage>. <pub-id pub-id-type="doi">10.1038/s41594-020-0440-6</pub-id><?supplied-pmid 32382072?><pub-id pub-id-type="pmid">32382072</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020a</year>). <article-title>Structure of M<sup>pro</sup> from SARS-CoV-2 and discovery of its inhibitors</article-title>. <source>Nature</source>
<volume>582</volume>, <fpage>289</fpage>&#x02013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id><?supplied-pmid 32272481?><pub-id pub-id-type="pmid">32272481</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S. U.</given-names></name><name><surname>Htar</surname><given-names>T.-T.</given-names></name></person-group> (<year>2020</year>). <article-title>Deciphering the binding mechanism of Dexamethasone against SARS-CoV-2 main protease: computational molecular modelling approach</article-title>. <source>ChemRxivorg. [Preprint].</source>
<pub-id pub-id-type="doi">10.26434/chemrxiv.12517535</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>M. M.</given-names></name><name><surname>Beumer</surname><given-names>J.</given-names></name><name><surname>van der Vaart</surname><given-names>J.</given-names></name><name><surname>Knoops</surname><given-names>K.</given-names></name><name><surname>Puschhof</surname><given-names>J.</given-names></name><name><surname>Breugem</surname><given-names>T. I.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>SARS-CoV-2 productively infects human gut enterocytes</article-title>. <source>Science</source>
<volume>369</volume>, <fpage>50</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1126/science.abc1669</pub-id><?supplied-pmid 32358202?><pub-id pub-id-type="pmid">32358202</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levites</surname><given-names>Y.</given-names></name><name><surname>Amit</surname><given-names>T.</given-names></name><name><surname>Mandel</surname><given-names>S.</given-names></name><name><surname>Youdim</surname><given-names>M. B. H.</given-names></name></person-group> (<year>2003</year>). <article-title>Neuroprotection and neurorescue against A&#x00026;beta;toxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)- epigallocatechin-3-gallate</article-title>. <source>Faseb J.</source>
<volume>17</volume>, <fpage>952</fpage>&#x02013;<lpage>954</lpage>. <pub-id pub-id-type="doi">10.1096/fj.02-0881fje</pub-id><pub-id pub-id-type="pmid">12670874</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.-H.</given-names></name><name><surname>Jang</surname><given-names>J.-H.</given-names></name><name><surname>Sun</surname><given-names>B.</given-names></name><name><surname>Surh</surname><given-names>Y.-J.</given-names></name></person-group> (<year>2004</year>). <article-title>Protective effects of oligomers of grape seed polyphenols against beta-amyloid-induced oxidative cell death</article-title>. <source>Ann. NY Acad. Sci.</source>
<volume>1030</volume>, <fpage>317</fpage>&#x02013;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1329.040</pub-id><?supplied-pmid 15659813?><pub-id pub-id-type="pmid">15659813</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y. J.</given-names></name><name><surname>Gao</surname><given-names>L. P.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>Z. W.</given-names></name><name><surname>Nie</surname><given-names>Z. Y.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Purification and characterization of a novel galloyltransferase involved in catechin galloylation in the tea plant (<italic>Camellia sinensis</italic>)</article-title>. <source>J. Biol. Chem.</source>
<volume>287</volume>, <fpage>44406</fpage>&#x02013;<lpage>44417</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.403071</pub-id><?supplied-pmid 23132863?><pub-id pub-id-type="pmid">23132863</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loke</surname><given-names>W. M.</given-names></name><name><surname>Hodgson</surname><given-names>J. M.</given-names></name><name><surname>Proudfoot</surname><given-names>J. M.</given-names></name><name><surname>McKinley</surname><given-names>A. J.</given-names></name><name><surname>Puddey</surname><given-names>I. B.</given-names></name><name><surname>Croft</surname><given-names>K. D.</given-names></name></person-group> (<year>2008</year>). <article-title>Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men</article-title>. <source>Am. J. Clin. Nutr.</source>
<volume>88</volume>, <fpage>1018</fpage>&#x02013;<lpage>1025</lpage>
<pub-id pub-id-type="doi">10.1093/ajcn/88.4.1018</pub-id><?supplied-pmid 18842789?><pub-id pub-id-type="pmid">18842789</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Serrano</surname><given-names>M.</given-names></name><name><surname>Barcelo</surname><given-names>A. R.</given-names></name></person-group> (<year>1997</year>). <article-title>Kinetic properties of (+)-catechin oxidation by a basic peroxidase ioenzyme from strawberries</article-title>. <source>J. Food Sci.</source>
<volume>62</volume>, <fpage>676</fpage>&#x02013;<lpage>723</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2621.1997.tb15433.x</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacRae</surname><given-names>K.</given-names></name><name><surname>Connolly</surname><given-names>K.</given-names></name><name><surname>Vella</surname><given-names>R.</given-names></name><name><surname>Fenning</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Epicatechin's cardiovascular protective effects are mediated via opioid receptors and nitric oxide</article-title>. <source>Eur. J. Nutr.</source>
<volume>58</volume>, <fpage>515</fpage>&#x02013;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1007/s00394-018-1650-0</pub-id><?supplied-pmid 29748816?><pub-id pub-id-type="pmid">29748816</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>K. B.</given-names></name><name><surname>Hurst</surname><given-names>W. J.</given-names></name><name><surname>Flannigan</surname><given-names>N.</given-names></name><name><surname>Ou</surname><given-names>B. X.</given-names></name><name><surname>Lee</surname><given-names>C. Y.</given-names></name><name><surname>Smith</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Survey of commercially available chocolate- and cocoa-containing products in the United States. 2. comparison of Flavan-3-ol content with nonfat cocoa solids, total polyphenols, and percent cacao</article-title>. <source>J. Agric. Food Chem</source>. <volume>57</volume>, <fpage>9169</fpage>&#x02013;<lpage>9180</lpage>. <pub-id pub-id-type="doi">10.1021/jf901821x</pub-id><?supplied-pmid 19754118?><pub-id pub-id-type="pmid">19754118</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molan</surname><given-names>A. L.</given-names></name><name><surname>Attwood</surname><given-names>G. T.</given-names></name><name><surname>Min</surname><given-names>B. R.</given-names></name><name><surname>McNabb</surname><given-names>W. C.</given-names></name></person-group> (<year>2001</year>). <article-title>The effect of condensed tannins from <italic>Lotus pedunculatus</italic> and <italic>Lotus corniculatus</italic> on the growth of proteolytic rumen bacteria <italic>in vitro</italic> and their possible mode of action</article-title>. <source>Can. J. Microbiol.</source>
<volume>47</volume>, <fpage>626</fpage>&#x02013;<lpage>633</lpage>. <pub-id pub-id-type="doi">10.1139/cjm-47-7-626</pub-id><?supplied-pmid 11547882?><pub-id pub-id-type="pmid">11547882</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monagas</surname><given-names>M.</given-names></name><name><surname>Gomez</surname><given-names>C. C.</given-names></name><name><surname>Bartolome</surname><given-names>B.</given-names></name><name><surname>Laureano</surname><given-names>O.</given-names></name><name><surname>da Ricardo</surname><given-names>S. J. M.</given-names></name></person-group> (<year>2003</year>). <article-title>Monomeric, oligomeric, and polymeric flavan-3-ol composition of wines and grapes from <italic>Vitis vinifera</italic> L. cv. <italic>Graciano</italic>, Tempranillo, and Cabernet Sauvignon</article-title>. <source>J. Agric. Food Chem.</source>
<volume>51</volume>, <fpage>6475</fpage>&#x02013;<lpage>6481</lpage>
<pub-id pub-id-type="doi">10.1021/jf030325+</pub-id><pub-id pub-id-type="pmid">14558765</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>K. J.</given-names></name><name><surname>Chronopoulos</surname><given-names>A. K.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name><name><surname>Francis</surname><given-names>M. A.</given-names></name><name><surname>Moriarty</surname><given-names>H.</given-names></name><name><surname>Pike</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Dietary flavanols and procyanidin oligomers from cocoa (<italic>Theobroma cacao</italic>) inhibit platelet function</article-title>. <source>Am. J. Clin. Nutr.</source>
<volume>77</volume>, <fpage>1466</fpage>&#x02013;<lpage>1473</lpage>
<pub-id pub-id-type="doi">10.1093/ajcn/77.6.1466</pub-id><pub-id pub-id-type="pmid">12791625</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohata</surname><given-names>M.</given-names></name><name><surname>Koyama</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Hayakawa</surname><given-names>S.</given-names></name><name><surname>Saeki</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Effects of tea constituents on cell cycle progression of human leukemia U937 cells</article-title>. <source>Biomed. Res.</source>
<volume>26</volume>, <fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2220/biomedres.26.1</pub-id><pub-id pub-id-type="pmid">15806977</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panneerselvam</surname><given-names>M.</given-names></name><name><surname>Tsutsumi</surname><given-names>Y. M.</given-names></name><name><surname>Bonds</surname><given-names>J. A.</given-names></name><name><surname>Horikawa</surname><given-names>Y. T.</given-names></name><name><surname>Saldana</surname><given-names>M.</given-names></name><name><surname>Dalton</surname><given-names>N. D.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Dark chocolate receptors: epicatechin-induced cardiac protection is dependent on delta-opioid receptor stimulation</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source>
<volume>299</volume>, <fpage>H1604</fpage>&#x02013;<lpage>H1609</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00073.2010</pub-id><?supplied-pmid 20833967?><pub-id pub-id-type="pmid">20833967</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillaiyar</surname><given-names>T.</given-names></name><name><surname>Manickam</surname><given-names>M.</given-names></name><name><surname>Namasivayam</surname><given-names>V.</given-names></name><name><surname>Hayashi</surname><given-names>Y.</given-names></name><name><surname>Jung</surname><given-names>S.-H.</given-names></name></person-group> (<year>2016</year>). <article-title>An overview of severe acute respiratory syndrome&#x02013;coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy</article-title>. <source>J. Med. Chem.</source>
<volume>59</volume>, <fpage>6595</fpage>&#x02013;<lpage>6628</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01461</pub-id><?supplied-pmid 26878082?><pub-id pub-id-type="pmid">26878082</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasanth</surname><given-names>D. S. N. B. K.</given-names></name><name><surname>Murahari</surname><given-names>M.</given-names></name><name><surname>Chandramohan</surname><given-names>V.</given-names></name><name><surname>Panda</surname><given-names>S. P.</given-names></name><name><surname>Atmakuri</surname><given-names>L. R.</given-names></name><name><surname>Guntupalli</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title><italic>In silico</italic> identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2</article-title>. <source>J. Biomol. Struct. Dyn</source>. <fpage>1</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1779129</pub-id><?supplied-pmid 32567989?><pub-id pub-id-type="pmid">32567989</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousserie</surname><given-names>P.</given-names></name><name><surname>Rabot</surname><given-names>A.</given-names></name><name><surname>Geny-Denis</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>From flavanols biosynthesis to wine tannins: what place for grape seeds?</article-title>
<source>J. Agric. Food Chem.</source>
<volume>67</volume>, <fpage>1325</fpage>&#x02013;<lpage>1343</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.8b05768</pub-id><?supplied-pmid 30632368?><pub-id pub-id-type="pmid">30632368</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>J. M.</given-names></name><name><surname>Monogue</surname><given-names>M. L.</given-names></name><name><surname>Jodlowski</surname><given-names>T. Z.</given-names></name><name><surname>Cutrell</surname><given-names>J. B.</given-names></name></person-group> (<year>2020</year>). <article-title>Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review</article-title>. <source>JAMA</source>
<volume>323</volume>, <fpage>1824</fpage>&#x02013;<lpage>1836</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.6019</pub-id><?supplied-pmid 32282022?><pub-id pub-id-type="pmid">32282022</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schewe</surname><given-names>T.</given-names></name><name><surname>Kuhn</surname><given-names>H.</given-names></name><name><surname>Sies</surname><given-names>H.</given-names></name></person-group> (<year>2002</year>). <article-title>Flavonoids of cocoa inhibit recombinant human 5-lipoxygenase</article-title>. <source>J. Nutr.</source>
<volume>132</volume>, <fpage>1825</fpage>&#x02013;<lpage>1829</lpage>
<pub-id pub-id-type="doi">10.1093/jn/132.7.1825</pub-id><?supplied-pmid 12097654?><pub-id pub-id-type="pmid">12097654</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schewe</surname><given-names>T.</given-names></name><name><surname>Sadik</surname><given-names>C.</given-names></name><name><surname>Klotz</surname><given-names>L. O.</given-names></name><name><surname>Yoshimoto</surname><given-names>T.</given-names></name><name><surname>Kuhn</surname><given-names>H.</given-names></name><name><surname>Sies</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>). <article-title>Polyphenols of cocoa: inhibition of mammalian 15-lipoxygenase</article-title>. <source>Biol. Chem.</source>
<volume>382</volume>, <fpage>1687</fpage>&#x02013;<lpage>1696</lpage>
<pub-id pub-id-type="doi">10.1515/BC.2001.204</pub-id><?supplied-pmid 11843182?><pub-id pub-id-type="pmid">11843182</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehailia</surname><given-names>M.</given-names></name><name><surname>Chemat</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19</article-title>. <source>J. Biomol. Struct. Dynamics</source>. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1080/07391102.2020.1796809</pub-id><?supplied-pmid 32696720?><pub-id pub-id-type="pmid">32696720</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvaraj</surname><given-names>V.</given-names></name><name><surname>Dapaah-Afriyie</surname><given-names>K.</given-names></name><name><surname>Finn</surname><given-names>A.</given-names></name><name><surname>Flanigan</surname><given-names>T. P.</given-names></name></person-group> (<year>2020</year>). <article-title>Short-term dexamethasone in Sars-CoV-2 patients</article-title>. <source>R I Med. J.</source>
<volume>103</volume>, <fpage>39</fpage>&#x02013;<lpage>43</lpage>. <?supplied-pmid 32570995?><pub-id pub-id-type="pmid">32570995</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serafini</surname><given-names>M.</given-names></name><name><surname>Bugianesi</surname><given-names>R.</given-names></name><name><surname>Maiani</surname><given-names>G.</given-names></name><name><surname>Valtuena</surname><given-names>S.</given-names></name><name><surname>de Santis</surname><given-names>S.</given-names></name><name><surname>Crozier</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>Plasma antioxidants from chocolate</article-title>. <source>Nature</source>
<volume>424</volume>:<fpage>1013</fpage>. <pub-id pub-id-type="doi">10.1038/4241013a</pub-id><?supplied-pmid 12944955?><pub-id pub-id-type="pmid">12944955</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suganuma</surname><given-names>M.</given-names></name><name><surname>Saha</surname><given-names>A.</given-names></name><name><surname>Fujiki</surname><given-names>H.</given-names></name></person-group> (<year>2011</year>). <article-title>New cancer treatment strategy using combination of green tea catechins and anticancer drugs</article-title>. <source>Cancer Sci.</source>
<volume>102</volume>, <fpage>317</fpage>&#x02013;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01805.x</pub-id><?supplied-pmid 21199169?><pub-id pub-id-type="pmid">21199169</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Kamiya</surname><given-names>T.</given-names></name><name><surname>Hasegawa</surname><given-names>A.</given-names></name><name><surname>Yokoo</surname><given-names>Y.</given-names></name></person-group> (<year>1999</year>). <article-title>Procyanidin oligomers selectively and intensively promote proliferation of mouse hair epithelial cells <italic>in vitro</italic> and activate hair follicle growth <italic>in vivo</italic></article-title>. <source>J. Invest. Dermatol.</source>
<volume>112</volume>, <fpage>310</fpage>&#x02013;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1747.1999.00532.x</pub-id><?supplied-pmid 10084307?><pub-id pub-id-type="pmid">10084307</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Bushmaker</surname><given-names>T.</given-names></name><name><surname>Morris</surname><given-names>D. H.</given-names></name><name><surname>Holbrook</surname><given-names>M. G.</given-names></name><name><surname>Gamble</surname><given-names>A.</given-names></name><name><surname>Williamson</surname><given-names>B. N.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1</article-title>. <source>N Engl. J. Med.</source>
<volume>382</volume>, <fpage>1564</fpage>&#x02013;<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2004973</pub-id><?supplied-pmid 32182409?><pub-id pub-id-type="pmid">32182409</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Horby</surname><given-names>P. W.</given-names></name><name><surname>Hayden</surname><given-names>F. G.</given-names></name><name><surname>Gao</surname><given-names>G. F.</given-names></name></person-group> (<year>2020</year>). <article-title>A novel coronavirus outbreak of global health concern</article-title>. <source>Lancet</source>
<volume>395</volume>, <fpage>470</fpage>&#x02013;<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30185-9</pub-id><?supplied-pmid 31986257?><pub-id pub-id-type="pmid">31986257</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) <italic>in vitro</italic></article-title>. <source>Cell Res.</source>
<volume>30</volume>, <fpage>269</fpage>&#x02013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><?supplied-pmid 32020029?><pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Hou</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Functional demonstration of plant flavonoid carbocations proposed to be involved in the biosynthesis of proanthocyanidins</article-title>. <source>Plant J.</source>
<volume>101</volume>, <fpage>18</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1111/tpj.14515</pub-id><?supplied-pmid 31454118?><pub-id pub-id-type="pmid">31454118</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinreb</surname><given-names>O.</given-names></name><name><surname>Mandel</surname><given-names>S.</given-names></name><name><surname>Amit</surname><given-names>T.</given-names></name><name><surname>Youdim</surname><given-names>M. B. H.</given-names></name></person-group> (<year>2004</year>). <article-title>Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases</article-title>. <source>J. Nutr. Biochem.</source>
<volume>15</volume>, <fpage>506</fpage>&#x02013;<lpage>516</lpage>
<pub-id pub-id-type="doi">10.1016/j.jnutbio.2004.05.002</pub-id><?supplied-pmid 15350981?><pub-id pub-id-type="pmid">15350981</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group> (<year>2020a</year>). <source>Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV).</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</mixed-citation></ref><ref id="B53"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group> (<year>2020b</year>). <source>WHO Director-General's Opening Remarks at the Media Briefing on COVID-19 - 11 March 2020</source>. <publisher-name>World Health Organization</publisher-name>
<publisher-loc>Geneva: Switzerland</publisher-loc>.</mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.-C.</given-names></name><name><surname>Chen</surname><given-names>C.-S.</given-names></name><name><surname>Chan</surname><given-names>Y.-J.</given-names></name></person-group> (<year>2020</year>). <article-title>The outbreak of COVID-19: an overview</article-title>. <source>J. Chin. Med. Assoc.</source>
<volume>83</volume>, <fpage>217</fpage>&#x02013;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1097/JCMA.0000000000000270</pub-id><?supplied-pmid 32134861?><pub-id pub-id-type="pmid">32134861</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Evidence for gastrointestinal infection of SARS-CoV-2</article-title>. <source>Gastroenterology</source>
<volume>158</volume>, <fpage>1831.e3</fpage>&#x02013;<lpage>1833.e3</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2020.02.055</pub-id><?supplied-pmid 32142773?><pub-id pub-id-type="pmid">32142773</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>D.-Y.</given-names></name><name><surname>Dixon</surname><given-names>R. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Proanthocyanidin biosynthesis - still more questions than answers?</article-title>
<source>Phytochemistry</source>
<volume>66</volume>, <fpage>2127</fpage>&#x02013;<lpage>2144</lpage>. <pub-id pub-id-type="doi">10.1016/j.phytochem.2005.01.008</pub-id><?supplied-pmid 16153412?><pub-id pub-id-type="pmid">16153412</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Xue</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Structures of two coronavirus main proteases: Implications for substrate binding and antiviral drug design</article-title>. <source>J. Virol.</source>
<volume>82</volume>, <fpage>2515</fpage>&#x02013;<lpage>2527</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02114-07</pub-id><?supplied-pmid 18094151?><pub-id pub-id-type="pmid">18094151</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuzuak</surname><given-names>S.</given-names></name><name><surname>Ballington</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>D. Y.</given-names></name></person-group> (<year>2018</year>). <article-title>HPLC-qTOE-MS/MS-based profiling of flavan-3-ols and dimeric proanthocyanidins in berries of two muscadine grape hybrids FLH 13-11 and FLH 17-66</article-title>. <source>Metabolites</source>
<volume>8</volume>:<fpage>57</fpage>. <pub-id pub-id-type="doi">10.3390/metabo8040057</pub-id><?supplied-pmid 30261603?><pub-id pub-id-type="pmid">30261603</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Curth</surname><given-names>U.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Sauerhering</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#x003b1;-ketoamide inhibitors</article-title>. <source>Science</source>
<volume>368</volume>, <fpage>409</fpage>&#x02013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb3405</pub-id><?supplied-pmid 32198291?><pub-id pub-id-type="pmid">32198291</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>X. L.</given-names></name><name><surname>Qian</surname><given-names>Y. M.</given-names></name><name><surname>Wang</surname><given-names>P. Q.</given-names></name><name><surname>Xie</surname><given-names>D. Y.</given-names></name><name><surname>Gao</surname><given-names>L. P.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Metabolic characterization of the anthocyanidin reductase pathway involved in the biosynthesis of Flavan-3-ols in elite Shuchazao Tea (<italic>Camellia sinensis</italic>) cultivar in the field</article-title>. <source>Molecules</source>
<volume>22</volume>:<fpage>21</fpage>. <pub-id pub-id-type="doi">10.3390/molecules22122241</pub-id><?supplied-pmid 29244739?><pub-id pub-id-type="pmid">29244739</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>Q. Z.</given-names></name><name><surname>Li</surname><given-names>K. G.</given-names></name><name><surname>Xie</surname><given-names>D. Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Molecular cloning and functional characterization of the anthocyanidin reductase gene from <italic>Vitis bellula</italic></article-title>. <source>Planta</source>
<volume>240</volume>, <fpage>381</fpage>&#x02013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1007/s00425-014-2094-2</pub-id><?supplied-pmid 24880552?><pub-id pub-id-type="pmid">24880552</pub-id></mixed-citation></ref></ref-list></back></article>